Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|January 5, 2002
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individualsBarbara Savoldo, Michael L Cubbage, April G Durett, et al.
Plos One|June 7, 2013
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cellsHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 12, 2014
Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanomaMarie-Andrée Forget, Shruti Malu, Hui Liu, et al.
Scientific Reports|February 23, 2012
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapyColleen M O'Connor, Sabina Sheppard, Cassie A Hartline, et al.
Cancer Research|September 3, 2015
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor ActivityHillary G Caruso, Lenka V Hurton, Amer Najjar, et al.
Blood|November 16, 2004
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytesKarin C M Straathof, Catherine M Bollard, Uday Popat, et al.
Blood|October 31, 2008
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patientsChrystal U Louis, Karin Straathof, Catherine M Bollard, et al.
Blood|October 24, 2002
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infectionBarbara Savoldo, M Helen Huls, Zhensheng Liu, et al.
The Journal of Experimental Medicine|December 22, 2004
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseCatherine M Bollard, Laura Aguilar, Karin C Straathof, et al.
British Journal of Haematology|September 7, 2021
Adoptive immunotherapy with double-bright (CD56<sup>bright</sup> /CD16<sup>bright</sup> ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept studyLucia Silla, Vanessa Valim, Annelise Pezzi, et al.
Pageof 6